Approval Package for:

APPLICATION NUMBER: 125477Orig1s000

Trade Name: CYRAMZA

Generic Name: ramucirumab

Sponsor: Eli Lilly and Company

Approval Date: April 21, 2014

Indications: CYRAMZA is indicated for the treatment of advanced gastric cancer or gastro-esophageal junction adenocarcinoma, as a single-agent after prior fluoropyrimidine-or platinum-containing therapy.
## CONTENTS

<table>
<thead>
<tr>
<th>Reviews / Information Included in this NDA Review.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Approval Letter</td>
</tr>
<tr>
<td>Other Action Letters</td>
</tr>
<tr>
<td>Labeling</td>
</tr>
<tr>
<td>REMS</td>
</tr>
<tr>
<td>Summary Review</td>
</tr>
<tr>
<td>Officer/Employee List</td>
</tr>
<tr>
<td>Office Director Memo</td>
</tr>
<tr>
<td>Cross Discipline Team Leader Review</td>
</tr>
<tr>
<td>Medical Review(s)</td>
</tr>
<tr>
<td>Chemistry Review(s)</td>
</tr>
<tr>
<td>Environmental Assessment</td>
</tr>
<tr>
<td>Pharmacology Review(s)</td>
</tr>
<tr>
<td>Statistical Review(s)</td>
</tr>
<tr>
<td>Microbiology / Virology Review(s)</td>
</tr>
<tr>
<td>Clinical Pharmacology/Biopharmaceutics Review(s)</td>
</tr>
<tr>
<td>Other Reviews</td>
</tr>
<tr>
<td>Risk Assessment and Risk Mitigation Review(s)</td>
</tr>
<tr>
<td>Proprietary Name Review(s)</td>
</tr>
<tr>
<td>Administrative/Correspondence Document(s)</td>
</tr>
</tbody>
</table>
BLA 125477/0

Eli Lilly and Company
Attention: Deborah Norby
Associate Vice President, Regulatory Affairs
33 ImClone Drive
Branchburg, NJ 08876

Dear Ms. Norby:

Please refer to your Biologics License Application (BLA) dated August 23, 2013, received August 23, 2103, submitted under section 351(a) of the Public Health Service Act for CYRAMZA (ramucirumab).


LICENSING

We are issuing Department of Health and Human Services U.S. License No. 1891 to Eli Lilly and Company, Indianapolis, Indiana, under the provisions of section 351(a) of the Public Health Service Act controlling the manufacture and sale of biological products. The license authorizes you to introduce or deliver for introduction into interstate commerce, those products for which your company has demonstrated compliance with establishment and product standards.

Under this license, you are authorized to manufacture the product CYRAMZA (ramucirumab). CYRAMZA is indicated for the treatment of advanced gastric cancer or gastro-esophageal junction adenocarcinoma, as a single-agent after prior fluoropyrimidine-or platinum-containing therapy.

MANUFACTURING LOCATIONS

Under this license, you are approved to manufacture CYRAMZA drug substance at ImClone Systems LLC in Branchburg, NJ. The final formulated product will be manufactured, filled, labeled, and packaged at Eli Lilly and Company in Indianapolis, Indiana. You may label your product with the proprietary name, CYRAMZA, and will market it in 100 mg/10 mL and 500 mg/50 mL single-dose vials.
**DATING PERIOD**

The dating period for CYRAMZA shall be 36 months from the date of manufacture when stored at 2-8 °C. The date of manufacture shall be defined from the date of manufacture when stored. The dating period for your drug substance shall be from the date of manufacture when stored.

**FDA LOT RELEASE**

You are not currently required to submit samples of future lots of CYRAMZA to the Center for Drug Evaluation and Research (CDER) for release by the Director, CDER, under 21 CFR 610.2. We will continue to monitor compliance with 21 CFR 610.1, requiring completion of tests for conformity with standards applicable to each product prior to release of each lot.

Any changes in the manufacturing, testing, packaging, or labeling of CYRAMZA, or in the manufacturing facilities, will require the submission of information to your biologics license application for our review and written approval, consistent with 21 CFR 601.12.

**APPROVAL & LABELING**

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling text.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit, via the FDA automated drug registration and listing system (eLIST), the content of labeling [21 601.14(b)] in structured product labeling (SPL) format, as described at [http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm](http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm). Content of labeling must be identical to the enclosed labeling text for the package insert. Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at [http://www.fda.gov/downloads/Drugs/GuidanceCompliance RegulatoryInformation/Guidances/UCM072392.pdf](http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf).

The SPL will be accessible via publicly available labeling repositories.

**CARTON AND IMMEDIATE CONTAINER LABELS**

We acknowledge your March 12, 2014, submission containing final printed carton and container labels. Submit final printed carton and container labels that are identical to the enclosed carton and immediate container labels, as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to the guidance for industry titled “Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (June 2008)”.

Reference ID: 3493067
Alternatively, you may submit 12 paper copies, with 6 of the copies individually mounted on heavy-weight paper or similar material. For administrative purposes, designate this submission “Product Correspondence – Final Printed Carton and Container Labels for approved BLA 125477/0.” Approval of this submission by FDA is not required before the labeling is used.

Marketing the product with final printed labeling (FPL) that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

**ADVISORY COMMITTEE**

Your application for CYRAMZA was not referred to an FDA advisory committee because this application did not raise significant safety or efficacy issues that were unexpected in the intended population.

**REQUIRED PEDIATRIC ASSESSMENTS**

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because this drug product for this indication has an orphan drug designation, you are exempt from this requirement.

**POSTMARKETING REQUIREMENTS UNDER 505(o)**

Section 505(o)(3) of the Federal Food, Drug, and Cosmetic Act (FDCA) authorizes FDA to require holders of approved drug and biological product applications to conduct postmarketing studies and clinical trials for certain purposes, if FDA makes certain findings required by the statute.

We have determined that an analysis of spontaneous postmarketing adverse events reported under subsection 505(k)(1) of the FDCA will not be sufficient to identify an unexpected serious risk of anti-drug antibody responses.

Furthermore, the new pharmacovigilance system that FDA is required to establish under section 505(k)(3) of the FDCA will not be sufficient to assess this serious risk.

Therefore, based on appropriate scientific data, FDA has determined that you are required to submit the following:

1. To submit a validation report for a validated, sensitive, and accurate assay for the detection of binding antibodies to ramucirumab, including procedures for the accurate detection of binding antibodies to ramucirumab in the presence of ramucirumab levels
that are expected to be present in the serum or plasma at the time of patient sampling.
The final report will be submitted as a Prior Approval Supplement.

The time table you submitted on March 12, 2014, states that you will conduct this study
according to the following schedule:

Final Report Submission: December 31, 2016

Finally, we have determined that only a clinical trial (rather than a nonclinical or observational
study) will be sufficient to address an unexpected serious risk of anti-drug antibody responses.

Therefore, based on appropriate scientific data, FDA has determined that you are required to
conduct the following:

2. To conduct an assessment of the anti-drug antibody (ADA) response to ramucirumab
   with a validated assay (required in PMR #1) capable of sensitively detecting ADA
   responses in the presence of ramucirumab levels that are expected to be present at the
time of patient sampling. The ADA response will be evaluated in at least 300 patients.

   The time table you submitted on March 12, 2014, states that you will conduct this trial
according to the following schedule:

   Final Report Submission: December 31, 2018

Submit the protocol(s) to your IND 11856, with a cross-reference letter to this BLA. Submit all
final reports to your BLA. Prominently identify the submission with the following wording in
bold capital letters at the top of the first page of the submission, as appropriate: “Required
Postmarketing Protocol Under 505(o)”, “Required Postmarketing Final Report Under
505(o)”, “Required Postmarketing Correspondence Under 505(o)”.

Section 505(o)(3)(E)(ii) of the FDCA requires you to report periodically on the status of any
study or clinical trial required under this section. This section also requires you to periodically
report to FDA on the status of any study or clinical trial otherwise undertaken to investigate a
safety issue. Section 506B of the FDCA, as well as 21 CFR 601.70 requires you to report
annually on the status of any postmarketing commitments or required studies or clinical trials.

FDA will consider the submission of your annual report under section 506B and 21 CFR 601.70
to satisfy the periodic reporting requirement under section 505(o)(3)(E)(ii) provided that you
include the elements listed in 505(o) and 21 CFR 601.70. We remind you that to comply with
505(o), your annual report must also include a report on the status of any study or clinical trial
otherwise undertaken to investigate a safety issue. Failure to submit an annual report for studies
or clinical trials required under 505(o) on the date required will be considered a violation of
FDCA section 505(o)(3)(E)(ii) and could result in enforcement action.
POSTMARKETING COMMITMENTS NOT SUBJECT TO THE REPORTING REQUIREMENTS UNDER SECTION 506B

We remind you of your postmarketing commitments:

3. To re-evaluate ramucirumab drug substance lot release and stability specifications after lots have been manufactured using the commercial manufacturing process. You will submit the corresponding data, the analytical and statistical plan used to evaluate the specifications, and any proposed changes to the specifications.

   The timetable you submitted on March 12, 2014, states that you will conduct this study according to the following schedule:

   Final Report Submission: December 31, 2015

4. To re-evaluate ramucirumab drug product lot release and stability specifications after lots have been manufactured using the commercial manufacturing process. You will submit the corresponding data, the analytic and statistical plan used to evaluate the specifications, and any proposed changes to the specifications.

   The timetable you submitted on March 12, 2014, states that you will conduct this study according to the following schedule:

   Final Report Submission: December 31, 2015

5. To confirm product stability using small scale studies. These studies will include testing for product quality (purity by using small scale studies. These studies will include testing for product quality (purity by (4) and potency of ramucirumab).

   The timetable you submitted on March 12, 2014, states that you will conduct this study according to the following schedule:

   Final Report Submission: November 30, 2015

6. To perform a shipping study to confirm validation of the commercial ramucirumab drug product shipping conditions. The study will include monitoring of temperature during the shipment, testing of pre- and post-shipping samples for product quality (purity by SEC, rSDS-PAGE, mSDS-PAGE, IEX, and potency of ramucirumab), and confirmation that the commercial shipping configuration minimizes physical damage to drug product containers.
The timetable you submitted on March 12, 2014, states that you will conduct this study according to the following schedule:

Final Report Submission: April 30, 2015

Submit nonclinical and chemistry, manufacturing, and controls protocols and all postmarketing final reports to this BLA. In addition, under 21 CFR 601.70 you should include a status summary of each commitment in your annual progress report of postmarketing studies to this BLA. The status summary should include expected summary completion and final report submission dates, any changes in plans since the last annual report, and, for clinical studies/trials, number of patients entered into each study/trial. All submissions, including supplements, relating to these postmarketing commitments should be prominently labeled “Postmarketing Commitment Protocol,” “Postmarketing Commitment Final Report,” or “Postmarketing Commitment Correspondence.”

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit, in triplicate, a cover letter requesting advisory comments, the proposed materials in draft or mock-up form with annotated references, and the package insert to:

    Food and Drug Administration
    Center for Drug Evaluation and Research
    Office of Prescription Drug Promotion
    5901-B Ammendale Road
    Beltsville, MD 20705-1266

As required under 21 CFR 601.12(f)(4), you must submit final promotional materials, and the package insert, at the time of initial dissemination or publication, accompanied by a Form FDA 2253. Form FDA 2253 is available at http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf. Information and Instructions for completing the form can be found at http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm.
REPORTING REQUIREMENTS

You must submit adverse experience reports under the adverse experience reporting requirements for licensed biological products (21 CFR 600.80). You should submit postmarketing adverse experience reports to:

Food and Drug Administration  
Center for Drug Evaluation and Research  
Central Document Room  
5901-B Ammendale Road  
Beltsville, MD  20705-1266

Prominently identify all adverse experience reports as described in 21 CFR 600.80.

You must submit distribution reports under the distribution reporting requirements for licensed biological products (21 CFR 600.81).

You must submit reports of biological product deviations under 21 CFR 600.14. You should promptly identify and investigate all manufacturing deviations, including those associated with processing, testing, packing, labeling, storage, holding and distribution. If the deviation involves a distributed product, may affect the safety, purity, or potency of the product, and meets the other criteria in the regulation, you must submit a report on Form FDA-3486 to:

Food and Drug Administration  
Center for Drug Evaluation and Research  
Division of Compliance Risk Management and Surveillance  
5901-B Ammendale Road  
Beltsville, MD  20705-1266

Biological product deviations, sent by courier or overnight mail, should be addressed to:

Food and Drug Administration  
Center for Drug Evaluation and Research  
Division of Compliance Risk Management and Surveillance  
10903 New Hampshire Avenue, Bldg. 51, Room 4206  
Silver Spring, MD  20903

MEDWATCH-TO-MANUFACTURER PROGRAM

The MedWatch-to-Manufacturer Program provides manufacturers with copies of serious adverse event reports that are received directly by the FDA. New molecular entities and important new biologics qualify for inclusion for three years after approval. Your firm is eligible to receive copies of reports for this product. To participate in the program, please see the enrollment instructions and program description details at http://www.fda.gov/Safety/MedWatch/HowToReport/ucm166910.htm.
POST APPROVAL FEEDBACK MEETING

New molecular entities and new biologics qualify for a post approval feedback meeting. Such meetings are used to discuss the quality of the application and to evaluate the communication process during drug development and marketing application review. The purpose is to learn from successful aspects of the review process and to identify areas that could benefit from improvement. If you would like to have such a meeting with us, call the Regulatory Project Manager for this application.

PDUFA V APPLICANT INTERVIEW

FDA has contracted with Eastern Research Group, Inc. (ERG) to conduct an independent interim and final assessment of the Program for Enhanced Review Transparency and Communication for NME NDAs and Original BLAs under PDUFA V (‘the Program’). The PDUFA V Commitment Letter states that these assessments will include interviews with applicants following FDA action on applications reviewed in the Program. For this purpose, first-cycle actions include approvals, complete responses, and withdrawals after filing. The purpose of the interview is to better understand applicant experiences with the Program and its ability to improve transparency and communication during FDA review.

ERG will contact you to schedule a PDUFA V applicant interview and provide specifics about the interview process. Your responses during the interview will be confidential with respect to the FDA review team. ERG has signed a non-disclosure agreement and will not disclose any identifying information to anyone outside their project team. They will report only anonymized results and findings in the interim and final assessments. Members of the FDA review team will be interviewed by ERG separately. While your participation in the interview is voluntary, your feedback will be helpful to these assessments.

If you have any questions, please call Ms. Sharon Sickafuse, Senior Regulatory Health Project Manager, at (301) 796-2320.

Sincerely,

Richard Pazdur, M.D.
Director
Office of Hematology and Oncology Products
Center for Drug Evaluation and Research

ENCLOSURES:
Content of Labeling
Carton and Container Labeling
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

RICHARD PAZDUR
04/21/2014